Boban Blagaic Alenka, Blagaic Vladimir, Mirt Mirela, Jelovac Nikola, Dodig Goran, Rucman Rudolf, Petek Marijan, Turkovic Branko, Anic Tomislav, Dubovecak Miroslav, Staresinic Mario, Seiwerth Sven, Sikiric Predrag
Department of Pharmacology, Medical Faculty, University of Zagreb, Salata 11, POB 916, 10000 Zagreb, Croatia.
Eur J Pharmacol. 2005 Apr 11;512(2-3):173-9. doi: 10.1016/j.ejphar.2005.02.033.
Serotonin syndrome commonly follows irreversible monoamine oxidase (MAO)-inhibition and subsequent serotonin (5-HT) substrate (in rats with fore paw treading, hind limbs abduction, wet dog shake, hypothermia followed by hyperthermia). A stable gastric pentadecapeptide BPC 157 with very safe profile (inflammatory bowel disease clinical phase II, PL-10, PLD-116, PL-14736, Pliva) reduced the duration of immobility to a greater extent than imipramine, and, given peripherally, has region specific influence on brain 5-HT synthesis (alpha-[14C]methyl-L-tryptophan autoradiographic measurements) in rats, different from any other serotonergic drug. Thereby, we investigate this peptide (10 microg, 10 ng, 10 pg/kg i.p.) in (i) full serotonin syndrome in rat combining pargyline (irreversible MAO-inhibition; 75 mg/kg i.p.) and subsequent L-tryptophan (5-HT precursor; 100 mg/kg i.p.; BPC 157 as a co-treatment), or (ii, iii) using pargyline or L-tryptophan given separately, as a serotonin-substrate with (ii) pargyline (BPC 157 as a 15-min posttreatment) or as a potential serotonin syndrome inductor with (iii) L-tryptophan (BPC 157 as a 15 min-pretreatment). In all experiments, gastric pentadecapeptide BPC 157 contrasts with serotonin-syndrome either (i) presentation (i.e., particularly counteracted) or (ii) initiation (i.e., neither a serotonin substrate (counteraction of pargyline), nor an inductor for serotonin syndrome (no influence on L-tryptophan challenge)). Indicatively, severe serotonin syndrome in pargyline + L-tryptophan rats is considerably inhibited even by lower pentadecapeptide BPC 157 doses regimens (particularly disturbances such as hyperthermia and wet dog shake thought to be related to stimulation of 5-HT2A receptors), while the highest pentadecapeptide dose counteracts mild disturbances present in pargyline rats (mild hypothermia, feeble hind limbs abduction). Thereby, in severe serotonin syndrome, gastric pentadecapeptide BPC 157 (alone, no behavioral or temperature effect) has a beneficial activity, which is likely, particular, and mostly related to a rather specific counteraction of 5-HT2A receptors phenomena.
血清素综合征通常继发于不可逆的单胺氧化酶(MAO)抑制以及随后的血清素(5-HT)底物作用(表现为大鼠前爪踩踏、后肢外展、湿狗样抖动、体温先降低后升高)。一种具有非常安全特性的稳定胃十五肽BPC 157(炎症性肠病临床II期、PL - 10、PLD - 116、PL - 14736、普利瓦)比丙咪嗪更能显著缩短不动时间,并且经外周给药时,对大鼠脑5-HT合成具有区域特异性影响(α-[14C]甲基-L-色氨酸放射自显影测量),这与其他任何血清素能药物不同。因此,我们研究该肽(10微克、10纳克、10皮克/千克腹腔注射)在以下情况中的作用:(i)在大鼠完全血清素综合征模型中,联合使用帕吉林(不可逆MAO抑制;75毫克/千克腹腔注射)和随后的L-色氨酸(5-HT前体;100毫克/千克腹腔注射;BPC 157作为联合治疗药物);或者(ii、iii)分别单独使用帕吉林或L-色氨酸,其中(ii)将帕吉林作为血清素底物(BPC 157在15分钟后给药),或者(iii)将L-色氨酸作为潜在的血清素综合征诱导剂(BPC 157在15分钟前给药)。在所有实验中,胃十五肽BPC 157与血清素综合征在以下方面形成对比:(i)表现(即特别对抗)或(ii)引发(即既不是血清素底物(对帕吉林的对抗作用),也不是血清素综合征诱导剂(对L-色氨酸激发无影响))。值得注意的是,即使是较低剂量方案的十五肽BPC 157也能显著抑制帕吉林+L-色氨酸大鼠中的严重血清素综合征(特别是诸如体温过高和湿狗样抖动等被认为与5-HT2A受体刺激有关的紊乱症状),而最高剂量的十五肽可对抗帕吉林大鼠中出现的轻微紊乱症状(轻度体温过低、后肢外展无力)。因此,在严重血清素综合征中,胃十五肽BPC 157(单独使用,无行为或体温影响)具有有益作用,这可能特别且主要与对5-HT2A受体现象的相当特异性的对抗作用有关。